HBP.TO - Helix BioPharma Corp.

Toronto - Toronto Delayed Price. Currency in CAD
1.2000
+0.0500 (+4.35%)
At close: 3:49PM EDT
Stock chart is not supported by your current browser
Previous Close1.1500
Open1.1800
Bid1.1000 x 0
Ask1.2000 x 0
Day's Range1.1000 - 1.2000
52 Week Range0.2400 - 1.2900
Volume2,200
Avg. Volume22,570
Market Cap149.94M
Beta (3Y Monthly)1.20
PE Ratio (TTM)N/A
EPS (TTM)-0.0700
Earnings DateJun 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Helix BioPharma Corp. Board Changes

    RICHMOND HILL, Ontario, Oct. 10, 2019 -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the.

  • GlobeNewswire

    Helix BioPharma Corp. and Moffit Cancer Centre to Present at World Molecular Imaging Congress

    The poster presentation will take place at the World Molecular Imaging Congress (“WMIC”), which is taking place at the Palais des congrès de Montréal in Montréal, Quebec, Canada (http://www.wmis.org/2019-wmic/) on September 4th through the 7th, 2019. The presentation describes the use of functional imaging techniques to measure the effect of L-DOS47 on changing tumor pH in a pancreatic mouse model.  The pH effect can be measured by CEST MRI using a CT contrast agent iopamidol and by 31P-MRS with 3-aminopropyl phosphate (“3-APP”) as reporting agent.  In both cases, L-DOS47 injection is shown to induce a localized pH increase at the target tumor.   L-DOS47 pH effect may also have a direct impact on therapy as combined treatment of L-DOS7 with an anti-PD-1 antibody is more efficacious than either agent alone in a preliminary round of animal study.

  • GlobeNewswire

    Helix BioPharma Corp. Closes $7.0 Million Private Placement

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing of 13,725,000 units of the Company and the disposition of a 25% stake of its wholly-owned Polish subsidiary for aggregate gross proceeds of CAD $7,000,005. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $0.72 and have an expiry of five years from the date of issuance.

  • GlobeNewswire

    Helix Biopharma Corp. Receives U.S. FDA Approval for Phase Ib/II Pancreatic Trial

    Helix BioPharma Corp. (HBP.TO), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced that it has received approval from the U.S. Food and Drug Administration (“FDA”), to initiate a Phase Ib/II study of L-DOS47 and doxorubicin in advanced metastatic pancreatic cancer. This is an open label, non-randomized study designed to evaluate the safety, tolerability and preliminary activity of L-DOS47 in combination with doxorubicin in patients with metastatic pancreatic cancer who have progressed on at least two prior treatment regimens.

  • GlobeNewswire

    Helix Biopharma Corp. to Present at RHK Capital Conference in New York

    Helix BioPharma Corp. (HBP.TO), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that it will be presenting at the RHK Capital 2019 Disruptive Growth & Healthcare Conference (www.disruptnyc.com). RHK Capital’s Disruptive Growth & Healthcare Conference showcases life science companies that focus on solutions for unmet medical needs and growth companies with disruptive technologies and business models.  The 2019 Disruptive Growth & Healthcare Conference will be held on Wednesday, September 4th and Thursday, September 5th in New York. “We are pleased to present Helix at this venue,” said Dr. Heman Chao, Helix’s Chief Executive Officer.  “As part of the Company’s objective to increase awareness of the Company’s novel DOS47 tumor microenvironment platform, the Company will be actively participating in select conferences and non-deal roadshows during the second half of calendar 2019”.

  • GlobeNewswire

    Helix BioPharma Corp. Submits L-DOS47 IND Application With U.S. FDA for Pancreatic Cancer

    Helix BioPharma Corp. (HBP.TO), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the submission of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for approval to initiate a Phase I/II clinical study protocol with L-DOS47, to be given in combination with doxorubicin, for the treatment of metastatic pancreatic cancer. Pancreatic cancer is the seventh leading cause of cancer related deaths in the world.  In the United States alone, it is estimated that over 56,000 adults will be diagnosed with the disease and over 45,000 patients will succumb to the disease, this year.  The 5-year survival rate for those who suffer from late stage metastatic pancreatic cancer is 3%.

  • GlobeNewswire

    Helix BioPharma Corp. Announces Fiscal Third Quarter 2019 Results

    RICHMOND HILL, Ontario, June 11, 2019 -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug.

  • GlobeNewswire

    Helix BioPharma Corp. Initiates OTCQB Application and Hires U.S. Investor Relations Firm

    Helix BioPharma Corp. (HBP.TO), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced that it has commenced the process to have the Company’s common shares quoted on the OTCQB® Market exchange in the United States. The Company’s U.S. legal counsel, Sheppard Mullin, Richter and Hampton LLC will be acting as Principal American Liaison (“PAL”) in assisting the Company through the listing application process. Expanding to the OTCQB® will provide existing shareholders with an additional trading platform to the Toronto Stock Exchange in addition to introducing the Company to a broader range of institutional and retail investors in the U.S. Listing on the OTCQB® represents a first step in fulfilling the Company’s ambitions to list on a U.S. stock exchange, such as NASDAQ.

  • GlobeNewswire

    Helix BioPharma Corp. Closes Private Placement

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD507,960. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $0.72 and have an expiry of five years from the date of issuance.  Helix intends to use the net proceeds of the private placement for working capital and research and development activities.

  • GlobeNewswire

    L-DOS47 Phase II Randomized Study Advances to Second Cohort

    Helix BioPharma Corp. (HBP.TO), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, has announced that the Trial Steering Committee ("TSC") reviewed safety data from the first dosing cohort of the Company’s LDOS003 study.  No serious adverse events or dose limiting toxicities were observed.  TSC recommended that Helix begin enrollment of patients into the second dosing cohort. LDOS003 is a Phase II, open-label, randomized study of immunoconjugate L-DOS47 in combination with vinorelbine and cisplatin as compared to vinorelbine and cisplatin alone in patients with lung adenocarcinoma.

  • GlobeNewswire

    Helix BioPharma Corp. Closes Second Tranche of Private Placement

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a second tranche of a private placement financing for gross proceeds of CAD510,000. The Company is working on completing another private placement financing tranche by May 17, 2019. Each unit is comprised of one common share and one common share purchase warrant.

  • GlobeNewswire

    Helix BioPharma Corp. Closes First Tranche of Private Placement

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a first tranche of a private placement financing for gross proceeds of approximately CAD1,016,390. The Company expects to complete subsequent private placement financing tranches by May 17, 2019. Each unit is comprised of one common share and one common share purchase warrant.

  • GlobeNewswire

    Helix BioPharma Corp. Retains U.S. Legal and Capital Firms to Advise on U.S. Listing

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has retained Sheppard Mullin, Richter and Hampton LLC (“Sheppard Mullin”) and RHK Capital (“RHK”). Sheppard Mullin will advise the Company on U.S. general corporate matters and securities law as the Company looks towards the U.S. capital markets.

  • GlobeNewswire

    Helix BioPharma Corp. Reports Voting Results

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting results of the Company’s annual and special meeting of shareholders held on April 15, 2019 (the “Meeting”). There were 24 shareholders represented in person or by proxy at the Meeting holding 64,835,119 shares, representing approximately 61.14% of Helix’s total issued and outstanding shares.

  • Associated Press

    Helix Biopharma: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Richmond Hill, Ontario-based company said it had a loss of 2 cents. The company's shares closed at 38 cents. A year ago, they were trading at 69 cents. _____ This story was generated ...

  • GlobeNewswire

    Helix BioPharma Corp. Announces Fiscal Second Quarter 2019 Results

    RICHMOND HILL, Ontario, March 18, 2019 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing.

  • GlobeNewswire

    Helix BioPharma Corp. Closes Private Placement, Extends Period to Exercise Warrants and Provides Corporate Update

    Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has closed a private placement financing for gross proceeds of CAD609,450. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $0.72 and have an expiry of five years from the date of issuance.

  • GlobeNewswire

    Helix BioPharma Corp.: First Patient Dosed in a Phase II Randomized Study of L-DOS47 With Vinorelbine and Cisplatin

    Helix BioPharma Corp. (HBP.TO), (HBP.F) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce the first patient has been successfully dosed with L-DOS47, vinorelbine and cisplatin in its Phase IIB, open-label, randomized study in metastatic lung adenocarcinoma patients (LDOS003 study). The goals of the study are to compare the safety, tolerability and preliminary efficacy of L-DOS47 in combination with vinorelbine/cisplatin as compared to vinorelbine/cisplatin alone, in patients with lung cancer. Additional information about the trial can be found in the EU Clinical Trials Register (https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003015-34/PL).

  • GlobeNewswire

    Helix BioPharma Corp. and Moffitt Cancer Center to Present at the AACR Annual Meeting 2019 in Atlanta

    Helix BioPharma Corp. (HBP.TO), (HBP.TO) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that together with the Moffitt Cancer Center (“Moffitt”), a poster entitled “Improving survival in pancreatic cancer using Doxorubicin in combination with L-DOS47” will be presented at the American Association for Cancer Research (“AACR”) Annual Meeting 2019 which is taking place on March 29 – April 3, 2019 at the Georgia World Congress Center, Atlanta, Georgia, USA. The presentation will describe the use of a preclinical pancreatic mouse model to study the effects of L-DOS47 alone or in combination therapies. This model was generated by modifying a mouse pancreatic cancer cell line (Panc02) to express the human ceacam6 antigen that is recognized by L-DOS47.  The model is designed to be used for monotherapy L-DOS47 efficacy studies and for combination studies with various agents, including immunotherapies.

  • GlobeNewswire

    Helix BioPharma Corp. Provides Clinical Development and Strategic Corporate Update

    Helix BioPharma Corp. (HBP.TO), (HBP.F) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer today provides an update on the Company’s strategic plans. The Company extended its collaboration with the Moffitt Cancer Center as a result of preliminary studies that show L-DOS47 may increase the activity of a PD-1/PD-L1 inhibitor in treating pancreatic cancer.  Helix’s plan is to increase the clinical application of L-DOS47 with various combination treatments, including immunotherapies with checkpoint inhibitors.

  • GlobeNewswire

    Helix BioPharma Corp. Extends Annual Meeting Date

    Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received consent from the Toronto Stock Exchange to extend the date of its annual general meeting of shareholders to a date not later than April 18, 2019. The Company made the request to extend the date of the annual general meeting of shareholders as a result of ongoing discussions to divest a majority stake in its wholly owned Polish subsidiary, Helix Immuno-Oncology S.A., which the Company expects to put to a vote for shareholder approval.  Helix expects that the directors will call an annual meeting of shareholders in the coming weeks.

  • GlobeNewswire

    Helix BioPharma Corp. Closes Final Tranche of Private Placement

    Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a final tranche of a private placement financing for gross proceeds of CAD348,000. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $1.50 and have an expiry of five years from the date of issuance.  Helix intends to use the net proceeds of the private placement for working capital and research and development activities.

  • GlobeNewswire

    Helix BioPharma Corp. Closes Third Tranche of Private Placement

    Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a third tranche of a private placement financing for gross proceeds of CAD700,800. Helix closed the first and second tranches of the private placement on December 6, 2018 and December 20, 2018 for gross proceeds of CAD871,200 and CAD342,000, respectively. The Company expects to complete a final tranche of the private placement financing before the end of December.